Table 2.

Treatment characteristics (n=130)

Characteristics	All (n=130) Median (range)
Duration of ICI, weeks	6 (0–145)
No. of ICI doses before colitis	3 (1–34)
Duration of steroids, weeks	10 (0–147)
Type of ICI
Adjuvant anti-CTLA-4	10 (8%)
Combination anti-CTLA-4/PD-1	35 (27%)
Single agent anti-CTLA-4	73 (56%)
Single agent anti-PD-1	12 (9%)
Grade of colitis
I	5 (4%)
II	7 (5%)
III	98 (75%)
IV	20 (16%)
Intravenous steroids at any time
No	38 (29%)
Yes	92 (71%)
Infliximab
No	78 (60%)
Yes	52 (40%)
Flare of colitis
No	70 (54%)
Yes	60 (46%)
No. of patients retreated with anti-PD-1 monotherapy	49 (38%)
Best response (RECIST 1.1)
CR	12 (9%)
PR	32 (25%)
SD	36 (28%)
PD	50 (38%)
PD on/after ICI
No	47 (36%)
Yes	83 (64%)
Death
No	68 (52%)
Yes	62 (48%)

CR, complete response; ICI, immune checkpoint inhibition; PD, progressive disease; PR, partial response; SD, stable disease.